Payment overview · 2025
General Payments
$2,603.73
134 reported records · 23 companies
Healthcare provider profile · identity verified
Steve D Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, AL · NPI 1144338880
Verified facts
What the public records show
CMS Open Payments records show Steve D Johnson, M.D. received $2,603.73 in general payments during 2025 across 134 reported records.
Novo Nordisk Inc accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 556 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $388.19 | 14.9% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $312.85 | 12.0% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $286.94 | 11.0% | 15 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $245.24 | 9.4% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $202.03 | 7.8% | 10 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $188.11 | 7.2% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $135.48 | 5.2% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $134.61 | 5.2% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $103.20 | 4.0% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $87.86 | 3.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.05 | 3.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.49 | 3.0% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $68.15 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.44 | 2.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.12 | 2.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.19 | 1.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.97 | 1.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.11 | 0.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.59 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.05 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.90 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.60 | 0.6% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $13.56 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,603.73 | 134 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $245.24 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $201.03 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.85 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $191.82 | 10 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $188.11 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $187.16 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $182.46 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.90 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.21 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $135.48 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $134.61 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $115.99 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $89.78 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $88.40 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $87.86 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.05 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.38 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.38 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $68.15 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.38 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.44 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 312 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 113 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 205 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 556 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
205 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
556 | 91 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
312 | 60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 1109 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 998 | 221 |
| Gabapentin | Gabapentin | 996 | 160 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 915 | 231 |
| Atorvastatin Calcium | Atorvastatin Calcium | 911 | 219 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 847 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 846 | 193 |
| Furosemide | Furosemide | 764 | 196 |
| Potassium Chloride | Potassium Chloride | 719 | 178 |
| Quetiapine Fumarate | Quetiapine Fumarate | 655 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 144 |
| Ozempic | Semaglutide | 556 | 91 |
| Metformin Hcl | Metformin Hcl | 552 | 143 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 531 | 133 |
| Tramadol Hcl | Tramadol Hcl | 507 | 77 |
| Omeprazole | Omeprazole | 443 | 108 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 429 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 428 | 99 |
| Sertraline Hcl | Sertraline Hcl | 407 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 404 | 75 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 347 | 67 |
| Losartan Potassium | Losartan Potassium | 331 | 85 |
| Celecoxib | Celecoxib | 327 | 77 |
| Eliquis | Apixaban | 312 | 60 |
| Montelukast Sodium | Montelukast Sodium | 298 | 71 |
| Allopurinol | Allopurinol | 294 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 294 | 45 |
| Buspirone Hcl | Buspirone Hcl | 290 | 67 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 277 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 276 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 271 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 259 | 57 |
| Trazodone Hcl | Trazodone Hcl | 257 | 58 |
| Pregabalin | Pregabalin | 254 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 248 | 58 |
| Prednisone | Prednisone | 247 | 145 |
| Carvedilol | Carvedilol | 244 | 65 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 239 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 228 | 43 |
| Mirtazapine | Mirtazapine | 222 | 42 |
| Azithromycin | Azithromycin | 212 | 161 |
| Jardiance | Empagliflozin | 209 | 37 |
| Glimepiride | Glimepiride | 208 | 53 |
| Mounjaro | Tirzepatide | 205 | 33 |
| Xarelto | Rivaroxaban | 204 | 39 |
| Famotidine | Famotidine | 201 | 52 |
| Ondansetron Odt | Ondansetron | 198 | 63 |
| Lisinopril | Lisinopril | 195 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 192 | 40 |
| Spironolactone | Spironolactone | 192 | 55 |
| Simvastatin | Simvastatin | 190 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 189 | 46 |
| Alprazolam | Alprazolam | 180 | 34 |
| Donepezil Hcl | Donepezil Hcl | 180 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 173 | 35 |
| Ibuprofen | Ibuprofen | 173 | 39 |
| Metoclopramide Hcl | Metoclopramide Hcl | 171 | 36 |
| Meloxicam | Meloxicam | 158 | 37 |
| Atenolol | Atenolol | 155 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 44 |
| Benazepril Hcl | Benazepril Hcl | 149 | 40 |
| Bupropion Xl | Bupropion Hcl | 139 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 137 | 29 |
| Clonazepam | Clonazepam | 132 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 129 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 128 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 127 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 125 | 54 |
| Alendronate Sodium | Alendronate Sodium | 123 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 27 |
| Ezetimibe | Ezetimibe | 117 | 24 |
| Nitroglycerin | Nitroglycerin | 114 | 51 |
| Clonidine Hcl | Clonidine Hcl | 113 | 32 |
| Farxiga | Dapagliflozin Propanediol | 113 | 28 |
| Myrbetriq | Mirabegron | 108 | 23 |
| Synthroid | Levothyroxine Sodium | 108 | 22 |
| Amoxicillin | Amoxicillin | 105 | 77 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 19 |
| Warfarin Sodium | Warfarin Sodium | 97 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 94 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 33 |
| Finasteride | Finasteride | 92 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 16 |
| Cilostazol | Cilostazol | 89 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 88 | 63 |
| Dicyclomine Hcl | Dicyclomine Hcl | 86 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 84 | 19 |
| Memantine Hcl | Memantine Hcl | 84 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 83 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 83 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 23 |
| Meclizine Hcl | Meclizine Hcl | 80 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 80 | 19 |
| Fluconazole | Fluconazole | 76 | 31 |
| Chlorthalidone | Chlorthalidone | 75 | 16 |
| Naproxen | Naproxen | 75 | 27 |
| Estradiol | Estradiol | 72 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 15 |
| Valacyclovir | Valacyclovir Hcl | 71 | 28 |
| Levetiracetam | Levetiracetam | 70 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 11 |
| Entresto | Sacubitril/Valsartan | 69 | 11 |
| Lansoprazole | Lansoprazole | 69 | 15 |
| Linzess | Linaclotide | 67 | 20 |
| Ranolazine Er | Ranolazine | 67 | 17 |
| Cephalexin | Cephalexin | 66 | 51 |
| Silodosin | Silodosin | 66 | suppressed |
| Cefdinir | Cefdinir | 65 | 55 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 63 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 13 |
| Metformin Hcl Er | Metformin Hcl | 61 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 15 |
| Topiramate | Topiramate | 54 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 11 |
| Dulera | Mometasone/Formoterol | 50 | 17 |
| Ketoconazole | Ketoconazole | 50 | suppressed |
| Nystatin | Nystatin | 49 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Vascepa | Icosapent Ethyl | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 11 |
| Baclofen | Baclofen | 43 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Bumetanide | Bumetanide | 41 | 12 |
| Betamethasone Valerate | Betamethasone Valerate | 39 | 22 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 31 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Ramipril | Ramipril | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 29 |
| Testosterone | Testosterone | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 15 |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 11 |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 17 |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 15 |
| Sucralfate | Sucralfate | 26 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 24 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 24 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Metaxalone | Metaxalone | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Pindolol | Pindolol | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,603.73 · 134 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GARDASIL 9, General - Pain Management, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRINTELLIX, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, Zemaira | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error